- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01103856
Test of an Intervention to Improve HIV Care
Přehled studie
Postavení
Podmínky
Typ studie
Zápis (Aktuální)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
Texas
-
Houston, Texas, Spojené státy, 77030
- Ben Taub General Hospital
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
1) Hospitalized at BTGH; 2) expected to be in the hospital for at least one more night at the time of enrollment; 3) at least 18 years of age at enrollment; 4) able to speak English or Spanish; 5) HIV infected, whether previously diagnosed or diagnosed this hospital stay; 6) cognitively aware enough to provide informed consent and participate in the study. Patients who are temporarily cognitively incapacitated (e.g., from an acute process) will be followed and approached for enrollment if and when they are cognitively and physically capable of participating in the study.
Exclusion Criteria:
1) Intending to use a source of HIV primary care other than TSHC after discharge from the hospital, because TSHC-specific mentoring is not relevant to them and the data on their appointments after discharge cannot be tracked; 2) in the opinion of the primary medical team, likely to be discharged to an institutional setting; 3) in the opinion of the primary medical team caring for the patient, likely to die in the hospital or be discharged to hospice; 4) cognitive impairment that in the opinion of the primary medical team caring for the patient is not expected to improve by discharge; 5) prisoner at admission and expected to be discharged back to prison or jail; 6) having had an HIV primary care visit in at least 3 of the 4 previous quarter-years AND having had at least 3 consecutive HIV VL<400 c/mL over at least 6 months, the most recent of which is within 3 months of enrollment; 7) enrolled in any other research project with prospective follow-up; 8) already enrolled in this study at any time.
For the purposes of this study, "prisoner" will be defined in accordance with Federal regulations, as "any individual involuntarily confined or detained in a penal institution...[including] individuals sentenced to such an institution under a criminal or civil statute, individuals detained in other facilities by virtue of statutes or commitment procedures which provide alternatives to criminal prosecution or incarceration in a penal institution, and individuals detained pending arraignment, trial, or sentencing…Parolees who are detained in a treatment center as a condition of parole are prisoners; however, persons living in the community and sentenced to community-supervised monitoring, including parolees, are not prisoners." Parolees meeting the definition of prisoner will be ineligible for the study.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Singl
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: Patient Mentor Intervention
The patient mentor intervention from TSHC has been adapted to the inpatient setting.
Participants randomized to that arm will receive 2 sessions with a patient mentor during their hospitalization, as well as 5 phone call sessions over the 10 weeks after discharge and a brief meeting between the subject and the mentor when the subject attends their first outpatient visit at TSHC after discharge.
|
The first session includes an exploration of needs, barriers, and facilitators to HIV care.
HIV educational materials are introduced to identify areas of need.
Mentors will address concerns and possible barriers to care using their own experiences.
Mentors will encourage participants to set goals related to acquisition of care following discharge and how to address possible barriers to that goal.
The second session will reinforce the first session.
Mentors will call the patient 5 times over the 10 weeks after discharge.
These phone calls will be brief and goal centered, to either reinforce positive behavior if the patient is in care, or continue to help the patient re-engage in outpatient HIV care.
Ostatní jména:
|
Komparátor placeba: HIV transmission risk reduction
Participants randomized to the control arm will receive an attention control intervention delivered by a patient educator who is not an HIV patient mentor.
We will use a modified version of the RESPECT intervention for our attention control group.
Similar to the active intervention, these patients will receive 2 sessions in the hospital and 5 phone calls over 10 weeks after discharge.
|
The control intervention is a modification of the project RESPECT intervention.
We will use material from sessions 1, 2, and 3 of the RESPECT enhanced counseling intervention.
These interactions will include a personalized assessment of risk behaviors and changing condom use self-efficacy.
The second interaction will build on material covered during the first interaction, with additional focus on condom use attitudes.
The counselors will call the patient 5 times in the 10 weeks after discharge.
These phone-based sessions will be brief and goal centered, to reinforce safe HIV transmission behaviors.
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Engaged in outpatient HIV care
Časové okno: 6 Months
|
A composite of attending at least one HIV primary care visit within 30 days of discharge AND at least one between 31 and 180 days AND, for patient with an indication for ART, achieving a one log10 decrease in HIV VL or maintaining a VL <400 c/mL at 180 days after discharge.
|
6 Months
|
Sekundární výstupní opatření
Měření výsledku |
Časové okno |
---|---|
Completion of at least one HIV primary care visit at TSHC within 30 days of discharge, health services use, changes in CD4 cell count and HIV VL, and quality of life.
Časové okno: 6 Months
|
6 Months
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Thomas P Giordano, MD, MPH, Baylor College of Medicine
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 1R01MH085527-01A1 (Grant/smlouva NIH USA)
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na HIV infekce
-
Helsinki University Central HospitalUniversity of Turku; Oulu University Hospital; Kuopio University Hospital; Tampere...NáborHysterektomie | Antibiotika | Infection Post Op | ProfylaktickýFinsko
-
University of MalayaTeleflexNáborCLABSI - Central Line Associated Bloodstream InfectionMalajsie
-
Duke UniversityDokončenoCentral Line-associated Bloodstream Infection (CLABSI)Spojené státy
-
Catholic University of the Sacred HeartDokončenoCentral Line-associated Bloodstream Infection (CLABSI)
-
Sinocelltech Ltd.NáborHPV Infection Vaccine Safety SCT1000Čína
-
Johns Hopkins UniversityDokončenoCLABSI - Central Line Associated Bloodstream InfectionSpojené státy
-
Burdenko Neurosurgery InstituteDokončenoHyperglykémie | Kraniotomie | Infection Post OpItálie, Ruská Federace
-
National Taiwan University HospitalDokončenoCentral Line-associated Bloodstream Infection (CLABSI)Tchaj-wan
-
Princess Maxima Center for Pediatric OncologyUMC Utrecht; Dutch Cancer SocietyNáborCentral Line-associated Bloodstream Infection (CLABSI)Holandsko
-
Port Said UniversityNáborCentral Line-associated Bloodstream Infection (CLABSI)Egypt
Klinické studie na Patient Mentor Intervention
-
NYU Langone HealthNational Institute on Disability, Independent Living, and Rehabilitation... a další spolupracovníciNábor
-
Johns Hopkins Bloomberg School of Public HealthDokončenoHepatitida C | HIV | Chování při snižování rizikaSpojené státy
-
Yale UniversityEli Lilly and Company; Connecticut State, Department of Mental Health and Addiction...DokončenoSchizofrenie | Schizoafektivní porucha | Bipolární porucha | Psychotická depreseSpojené státy
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityDokončenoDiabetes mellitus 2. typu | Kardiometabolické stavy | Behaviorální zdravotní problémySpojené státy
-
Montefiore Medical CenterNational Institute on Drug Abuse (NIDA); Prisma Health-UpstateNáborHepatitida CSpojené státy
-
Indiana UniversityNational Institutes of Health (NIH); National Center for Advancing Translational... a další spolupracovníciZápis na pozvánkuStigma, sociální | Pre-expoziční profylaxe HIVKeňa
-
University of Alabama at BirminghamThe Craig H. Neilsen Foundation; Lakeshore FoundationDokončenoPoranění míchySpojené státy
-
Weill Medical College of Cornell UniversityDokončenoIschemická choroba srdečníSpojené státy
-
GE HealthcareUkončenoKrevní tlak (nízký, normální, vysoký)Spojené státy
-
Southeast University, ChinaNábor